Patients, Advocates and Medical Professionals:
For more information please contact:http://www.clinicaltrials.gov
Primary Liver Cancer (HCC): Phase II JX-594
North America (U.S. and Canada) and South Korea
We are currently recruiting for a clinical trial of JX-594 in patients with unresectable primary liver cancer (HCC) that has failed at least one prior therapy. For additional information on participating locations and eligibility requirements for enrollment into this study, please visit the National Institutes of Health clinical trials database at http://www.clinicaltrials.gov. Enter a search for clinicaltrials.gov identifier: NCT00554372.
Treatment-refractory Solid Tumors: Phase I JX-594
North America
We are currently recruiting for a clinical trial of JX-594 administered intravenously in patients with advanced/metastatic solid tumors refractory to standard therapy. Tumors may include non-small cell lung cancer, malignant melanoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, and other tumor types (e.g. colon). For additional information on participating locations and eligibility requirements for enrollment into this study, please visit the National Institutes of Health clinical trials database at http://www.clinicaltrials.gov. Enter a search for clinicaltrials.gov identifier: NCT00625456.
Treatment-refractory Solid Tumors: Phase I vvDD-CDSR (a.k.a. JX-929)
North America
The University of Pittsburgh Cancer Institute is currently recruiting for a clinical trial of vvDD-CDSR (also called JX-929). Tumors may include colorectal cancer, malignant melanoma, breast cancer, or head and neck squamous cell cancer. For additional information on eligibility requirements for enrollment into this trial, please visit the National Institutes of Health clinical trials database at http://www.clinicaltrials.gov. Enter a search for clinicaltrials.gov identifier: NCT00574977.
Back to Top